Background: Telomere length dysregulation plays a major role in cancer development and aging. Telomeres are maintained by a group of specialized genes known as shelterin and shelterin-associated proteins. In breast cancer lines it has been shown that shelterin proteins are dysregulated thereby affecting the telomere stability and contributing to the neoplastic conversion of the mammary epithelial cells. Interestingly, the regulation of some of the shelterin genes is thought to be controlled epigenetically. Methods and Results: In this study, we set out to measure the effect of increased shelterin gene expression on telomere length in breast cancer cell line 21NT treated with 5-aza-2-deoxycytidine (5-aza-CdR) using known telomere length assays. We measured telomere lengths using: Telomere Restriction Fragment length (TRF), absolute quantitative-PCR and cytogenetic Interphase Quantitative Fluorescent i n situ Hybridization ( iQ-FISH). We found that non-cytotoxic levels of 5-aza-CdR a ffect telomere lengths by causing a significant and stable increase in telomere lengths of the breast cancer cell line. The increase in telomere lengths w as consistently observed when various telomere length methods were used. Conclusions: Further investigation is required to understand the underlying mechanism involved, and the significance of telomere length elongation in relation to clinical outcome when epigenetic modifying drugs are utilized.
KeywordsTelomere5-Aza-2-deoxycytidine (5-aza-CdR)Trichostatin A (TSA)ShelteriniQ-FISHBreast Cancer
Jacobs, J.J. (2013) Loss of Telomere Protection: Consequences and Opportunities. Frontiers in Oncology, 3, 88. http://dx.doi.org/10.3389/fonc.2013.00088
Mather, K.A., Jorm, A.F., Parslow, R.A. and Christensen, H. (2011) Is Telomere Length a Biomarker of Aging? A Review. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 66, 202-213. http://dx.doi.org/10.1093/gerona/glq180
von Zglinicki, T. and Martin-Ruiz, C.M. (2005) Telomeres as Biomarkers for Ageing and Age-Related Diseases. Current Molecular Medicine, 5, 197-203. http://dx.doi.org/10.2174/1566524053586545
Collado, M., Blasco, M.A. and Serrano, M. (2007) Cellular Senescence in Cancer and Aging. Cell, 130, 223-233. http://dx.doi.org/10.1016/j.cell.2007.07.003
Sfeir, A. and de Lange, T. (2012) Removal of Shelterin Reveals the Telomere End-Protection Problem. Science, 336, 593-597. http://dx.doi.org/10.1126/science.1218498
Hanahan, D. and Weinberg, R.A. (2000) The Hallmarks of Cancer. Cell, 100, 57-70. http://dx.doi.org/10.1016/S0092-8674(00)81683-9
Hiyama, K. (2009) Telomeres and Telomerase in Cancer. Humana, Springer, London, Totowa. http://dx.doi.org/10.1007/978-1-60327-879-9
Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D., Ho, P.L., Coviello, G.M., Wright, W.E., Weinrich, S.L. and Shay, J.W. (1994) Specific Association of Human Telomerase Activity with Immortal Cells and Cancer. Science, 266, 2011-2015. http://dx.doi.org/10.1126/science.7605428
Donate, L.E. and Blasco, M.A. (2011) Telomeres in Cancer and Ageing. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 366, 76-84. http://dx.doi.org/10.1098/rstb.2010.0291
Salhab, M., Jiang, W.G., Newbold, R.F. and Mokbel, K. (2008) The Expression of Gene Transcripts of Telo-Mere-Associated Genes in Human Breast Cancer: Correlation with Clinico-Pathological Parameters and Clinical Outcome. Breast Cancer Research and Treatment, 109, 35-46. http://dx.doi.org/10.1007/s10549-007-9622-8
Butler, K.S., Hines, W.C., Heaphy, C.M. and Griffith, J.K. (2012) Coordinate Regulation between Expression Levels of Telomere-Binding Proteins and Telomere Length in Breast Carcinomas. Cancer Medicine, 1, 165-175. http://dx.doi.org/10.1002/cam4.14
Motevalli, A., Yasaei, H., Virmouni, S.A., Slijepcevic, P. and Roberts, T. (2014) The Effect of Chemotherapeutic Agents on Telomere Length Maintenance in Breast Cancer Cell Lines. Breast Cancer Research and Treatment, 145, 581-591. http://dx.doi.org/10.1007/s10549-014-2975-x
Benitez-Buelga, C., Sanchez-Barroso, L., Gallardo, M., Apellaniz-Ruiz, M., Inglada-Perez, L., Yanowski, K., Car-rillo, J., Garcia-Estevez, L., Calvo, I., Perona, R., Urioste, M., Osorio, A., Blasco, M.A., Rodriguez-Antona, C. and Benitez, J. (2015) Impact of Chemotherapy on Telomere Length in Sporadic and Familial Breast Cancer Patients. Breast Cancer Research and Treatment, 149, 385-394. http://dx.doi.org/10.1007/s10549-014-3246-6
Band, V., Zajchowski, D., Swisshelm, K., Trask, D., Kulesa, V., Cohen, C., Connolly, J. and Sager, R. (1990) Tumor Progression in Four Mammary Epithelial Cell Lines Derived from the Same Patient. Cancer Research, 50, 7351-7357.
McIlrath, J., Bouffler, S.D., Samper, E., Cuthbert, A., Wojcik, A., Szumiel, I., Bryant, P.E., Riches, A.C., Thompson, A., Blasco, M.A., Newbold, R.F. and Slijepcevic, P. (2001) Telomere Length Abnormalities in Mammalian Radiosensitive Cells. Cancer Research, 61, 912-915.
Yasaei, H. and Slijepcevic, P. (2010) Defective Artemis Causes Mild Telomere Dysfunction. Genome Integrity, 1, 3. http://dx.doi.org/10.1186/2041-9414-1-3
Garbe, J.C., Bhattacharya, S., Merchant, B., Bassett, E., Swisshelm, K., Feiler, H.S., Wyrobek, A.J. and Stampfer, M.R. (2009) Molecular Distinctions between Stasis and Telomere Attrition Senescence Barriers Shown by Long-Term Culture of Normal Human Mammary Epithelial Cells. Cancer Research, 69, 7557-7568. http://dx.doi.org/10.1158/0008-5472.CAN-09-0270
Kimura, M., Stone, R.C., Hunt, S.C., Skurnick, J., Lu, X., Cao, X., Harley, C.B. and Aviv, A. (2010) Measurement of Telomere Length by the Southern Blot Analysis of Terminal Restriction Fragment Lengths. Nature Protocols, 5, 1596-1607. http://dx.doi.org/10.1038/nprot.2010.124
Wang, F., Podell, E.R., Zaug, A.J., Yang, Y., Baciu, P., Cech, T.R. and Lei, M. (2007) The POT1-TPP1 Telomere Complex Is a Telomerase Processivity Factor. Nature, 445, 506-510. http://dx.doi.org/10.1038/nature05454
Hultdin, M., Gronlund, E., Norrback, K., Eriksson-Lindstrom, E., Just, T. and Roos, G. (1998) Telomere Analysis by Fluorescence in Situ Hybridization and Flow Cytometry. Nucleic Acids Research, 26, 3651-3656. http://dx.doi.org/10.1093/nar/26.16.3651
Slijepcevic, P. (2001) Telomere Length Measurement by Q-FISH. Methods in Cell Science, 23, 17-22. http://dx.doi.org/10.1023/A:1013177128297
Ojani, M. (2012) Relationship between DNA Damage Response and Telomere Maintenance. Brunel University, London.
Connolly, R. and Stearns, V. (2012) Epigenetics as a Therapeutic Target in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 17, 191-204. http://dx.doi.org/10.1007/s10911-012-9263-3
Ishikawa, T. (2014) Novel Therapeutic Strategies Using Hypomethylating Agents in the Treatment of Myelo-Dysplastic Syndrome. International Journal of Clinical Oncology, 19, 10-15. http://dx.doi.org/10.1007/s10147-013-0651-5
Ozbalak, M., Cetiner, M., Bekoz, H., Atesoglu, E.B., Ar, C., Salihoglu, A., Tuzuner, N. and Ferhanoglu, B. (2012) Azacitidine Has Limited Activity in “Real Life” Patients with MDS and AML: A Single Centre Experience. Hematological Oncology, 30, 76-81. http://dx.doi.org/10.1002/hon.986
Prebet, T., Gore, S.D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O.B., Recher, C., Ades, L., Quesnel, B., Beach, C.L., Fenaux, P. and Vey, N. (2011) Outcome of High-Risk Myelodysplastic Syndrome after Azacitidine Treatment Failure. Journal of Clinical Oncology, 29, 3322-3327. http://dx.doi.org/10.1200/JCO.2011.35.8135
Zeidan, A.M., Linhares, Y. and Gore, S.D. (2013) Current Therapy of Myelodysplastic Syndromes. Blood Reviews, 27, 243-259. http://dx.doi.org/10.1016/j.blre.2013.07.003
Vera, E. and Blasco, M.A. (2012) Beyond Average: Potential for Measurement of Short Telomeres. Aging, 4, 379-392. http://dx.doi.org/10.18632/aging.100462
Steinert, S., Shay, J.W. and Wright, W.E. (2004) Modification of Subtelomeric DNA. Molecular and Cellular Biology, 24, 4571-4580. http://dx.doi.org/10.1128/MCB.24.10.4571-4580.2004
Newbold, R.F. (2002) The Significance of Telomerase Activation and Cellular Immortalization in Human Cancer. Mutagenesis, 17, 539-550. http://dx.doi.org/10.1093/mutage/17.6.539
Ducrest, A.L., Amacker, M., Mathieu, Y.D., Cuthbert, A.P., Trott, D.A., Newbold, R.F., Nabholz, M. and Lingner, J. (2001) Regulation of Human Telomerase Activity: Repression by Normal Chromosome 3 Abolishes Nuclear Telomerase Reverse Transcriptase Transcripts but Does Not Affect c-Myc Activity. Cancer Research, 61, 7594-7602.
Vera, E., Canela, A., Fraga, M.F., Esteller, M. and Blasco, M.A. (2008) Epigenetic Regulation of Telomeres in Human Cancer. Oncogene, 27, 6817-6833. http://dx.doi.org/10.1038/onc.2008.289
Wang, F., Podell, E.R., Zaug, A.J., Yang, Y., Baciu, P., Cech, T.R. and Lei, M. (2007) The POT1-TPP1 Telomere Complex Is a Telomerase Processivity Factor. Nature, 445, 506-510. http://dx.doi.org/10.1038/nature05454
Hirashima, K., Migita, T., Sato, S., Muramatsu, Y., Ishikawa, Y. and Seimiya, H. (2013) Telomere Length Influences Cancer Cell Differentiation in Vivo. Molecular and Cellular Biology, 33, 2988-2995. http://dx.doi.org/10.1128/MCB.00136-13
Ko, E. and Jung, G. (2014) Positive Association of Long Telomeres with the Invasive Capacity of Hepatocellular Carcinoma Cells. Biochemical and Biophysical Research Communications, 447, 358-363. http://dx.doi.org/10.1016/j.bbrc.2014.04.022